Eli Lilly and Company LLY presented new efficacy data from studies of its marketed and investigational metabolic medicines at the annual European Association for the Study of Diabetes (EASD) conference. Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, is FDA-approved for chronic weight management in adults with obesity or certain adults with overweight and weight-related medical problems. Eli Lilly also reported results for EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist, and LLY's blockbuster obesity drug, Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, being developed for people with obesity or overweight and type II diabetes (T2D).
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.